Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05210088
Other study ID # 2021-A00104-37
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date September 1, 2023
Est. completion date December 31, 2025

Study information

Verified date May 2023
Source University Hospital, Grenoble
Contact Sébastien BAILLIEUL, MD, PhD
Phone 0623574355
Email sbaillieul@chu-grenoble.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

By inducing endogenous neuroprotection, hypoxic post-conditioning following stroke may represent a harmless and efficient non-pharmacological innovative neuro-therapeutic modality aiming at inducing neuroplasticity and brain repair, as supported by many preclinical studies. The investigators thus hypothesize that hypoxic post-conditioning represents a safe therapeutic strategy post-stroke. The investigators further hypothesize that hypoxic conditioning could enhance neuroplasticity and function in combination with conventional rehabilitative care. The primary study endpoint will be safety. Safety will be assessed through the clinical review of the adverse events over the duration of the study, every 48 hours by a trained evaluator, blinded for the therapeutic intervention. The investigators will further investigate the potential functional benefits of such a therapeutic approach on motor function, gait, balance, and cognition. The neurophysiological substrates of hypoxic conditioning-triggered neuroplasticity at a subacute delay post-stroke will also be investigated, based on biological and imagery markers.


Description:

Stroke is the second leading cause of death and the third leading cause of disability-adjusted life-years worldwide. If acute stroke therapy has decreased mortality, more than 50% of stroke survivors are left with sensorimotor and cognitive deficiencies. Recovery and rehabilitation treatments, aiming at inducing neuroplasticity, maximizing function in unaffected brain areas or implementing compensatory strategies to improve overall function, benefit from an extensive time window that ranges from days to months. Their development is urgently needed. Several endogenous neuroprotective mechanisms are spontaneously engaged following stroke to achieve neuroprotection and stimulate brain repairing processes. Conditioning the central nervous system can trigger endogenous mechanisms of neuroprotection. Conditioning refers to a procedure by which a potentially deleterious stimulus is applied near to but below the threshold of damage to the organism. While hypoxia is well recognized as a common underlying mechanism of many pathological conditions, experimental data indicate that exposure to specific doses of hypoxia (by breathing a hypoxic gas mixture) can be neuroprotective. Preconditioning is defined as the exposure to the conditioning stimulus before injury onset, to induce tolerance or resistance to the subsequent injury. Postconditioning refers to the application of the conditioning stimulus after injury or damage, to stimulate tissue reparation or neuroplasticity. As stroke is an unpredictable event, translating hypoxic preconditioning to clinical practice seems difficult. However, developing postconditioning strategies seems of clinical and rehabilitative relevance. Thus, an increase in neuronal salvage and neurogenesis, along with an increase in brain-derived neurotrophic factor expression and a reduced neuroinflammation were shown in murine models of hypoxic conditioning following ischemic stroke. By inducing endogenous neuroprotection, hypoxic conditioning may represent a harmless and efficient non-pharmacological innovative neuro-therapeutic modality aiming at inducing neuroplasticity and brain repair, as supported by many preclinical studies. The main working hypothesis is that hypoxic postconditioning may represent a safe therapeutic strategy post-stroke. The investigators further hypothesize that hypoxic conditioning could enhance neuroplasticity and function in combination with conventional rehabilitative care. The primary study endpoint will be safety. Safety will be assessed through the clinical review of the adverse events over the duration of the study, every 48 hours by a trained evaluator, blinded for the therapeutic intervention. All adverse events will be evaluated and quoted in accordance with National Institute of Health Common Criteria for Terminology for Adverse Events 5.0 (NIH CCTAE) recommendations, particularly with respect to Sub-sections "Cardiac disorders ", "Nervous system disorders" and "Vascular Disorders". Safety assessments will be performed every 48 hours, throughout the 8-week conditioning period, in addition to the conventional clinical follow-up performed in the rehabilitation unit. The potential functional benefits of such a therapeutic approach on motor function, gait, balance, and cognition will also be further investigated. The neurophysiological substrates of hypoxic conditioning-triggered neuroplasticity at a subacute delay post-stroke will be investigated, based on biological (serum inflammatory markers, growth and neurogenesis biomarkers) and imagery markers (morphological MRI sequences, functional connectivity (resting state), and brain vascularization).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date December 31, 2025
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Patients with minor cerebral infarction with NIHSS < or equal to 5 will be included in the protocol; - Cerebral infarction occurring one month (±1 week) before the planned start of hypoxic exposure; - Age =18 years; - A first, unilateral, ischemic, supra-tentorial hemispheric stroke, confirmed by magnetic resonance imaging; - Modified Rankin Scale score between 1 and 3, defining mild to moderate residual functional disability. - A person affiliated with the social security system or benefits from such a system; - A person who has given written informed consent. Exclusion Criteria: - Patients who are minors or over 85 years of age, pregnant or breastfeeding women, or women of childbearing potential in the absence of highly effective contraception; - Stroke of the brainstem or cerebellum ; - Severe aphasia, limiting the ability to understand the protocol; - History of central or peripheral neurological pathology; - Modified Rankin Scale score >0 before stroke; - Known severe untreated obstructive sleep apnea syndrome, defined as an apnea-hypopnea index = 30 events per hour of sleep; - Pre-existing hypoxemic lung disease (such as chronic obstructive pulmonary disease); - Heart failure, defined as an ejection fraction =40% ; - History of high altitude pathology; - Scheduled stay at altitude (> 2500 m) during the study period ; - Migraine; - History of rheumatological or orthopedic disease of the lower limbs, amputation of the lower limb. - Contraindication to magnetic resonance imaging; - Subjects who cannot be contacted in an emergency; - Subject in exclusion period of another study; - Subject under administrative or judicial supervision; - Persons referred to in Articles L1121-5 to L1121-8 of the "Code de la Santé Publique" (corresponds to all protected persons: pregnant women, women in labor, nursing mothers, persons deprived of their liberty by judicial or administrative decision, persons subject to a legal protection measure).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Hypoxia, intermittent
The device used to generate the intermittent hypoxia stimulus is a gas mixer used in current clinical practice and research (Altitrainer®, SMTEC S.A. Switzerland). The hypoxic stimulus will be obtained by having the subject inhale a gas mixture enriched in nitrogen by means of a mask, in variable proportion according to the desired degree of hypoxia. Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment. For hypoxic exposure, the inspired fraction of oxygen (FiO2) will be set individually to achieve the targeted level of desaturation (Pulse Oxygen Saturation, SpO2) continuously monitored.
Other:
Normoxia
The normoxic stimulus will be obtained by having the subjects inhale via a face mask a normoxic gas mixture with a fixed FiO2 of 21%, delivered by the gas mixing device (Altitrainer®, SMTEC S.A. Switzerland).

Locations

Country Name City State
France Grenoble Aalpes University Hospital Grenoble Veuillez Sélectionner Une Région.

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Grenoble Agir pour les maladies chroniques

Country where clinical trial is conducted

France, 

References & Publications (3)

Baillieul S, Chacaroun S, Doutreleau S, Detante O, Pepin JL, Verges S. Hypoxic conditioning and the central nervous system: A new therapeutic opportunity for brain and spinal cord injuries? Exp Biol Med (Maywood). 2017 Jun;242(11):1198-1206. doi: 10.1177/1535370217712691. — View Citation

Burtscher J, Syed MMK, Lashuel HA, Millet GP. Hypoxia Conditioning as a Promising Therapeutic Target in Parkinson's Disease? Mov Disord. 2021 Apr;36(4):857-861. doi: 10.1002/mds.28544. Epub 2021 Feb 27. — View Citation

Verges S, Chacaroun S, Godin-Ribuot D, Baillieul S. Hypoxic Conditioning as a New Therapeutic Modality. Front Pediatr. 2015 Jun 22;3:58. doi: 10.3389/fped.2015.00058. eCollection 2015. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Biomarkers of hypoxic conditioning - Brain Derived Neurotrophic Factor (BDNF) Phase 2 only. A blood sample collection will be performed to secondary assess the Brain-Derived Neurotrophic Factor (BDNF) levels in the serum.
Unit: pg/ml
Phase 2: Inclusion, 2 months, 6 months
Other Biomarkers of hypoxic conditioning - Erythropoietin (EPO) Phase 2 only. A blood sample collection will be performed to secondary assess the Erythropoietin (EPO) levels in the serum.
Unit: milli-international unit/mL
Phase 2: Inclusion, 2 months, 6 months
Other Biomarkers of hypoxic conditioning - Hypoxia inducible factor 1 Phase 2 only. A blood sample collection will be performed to secondary assess the Hypoxia inducible factor 1 levels in the blood.
Analytic method: RNA extraction Unit: Normalised copy number
Phase 2: Inclusion, 2 months, 6 months
Other Biomarkers of hypoxic conditioning - Vascular Endothelial Growth Factor (VEGF) Phase 2 only. A blood sample collection will be performed to secondary assess the VEGF levels in the blood.
Analytic method: ELISA
Phase 2: Inclusion, 2 months, 6 months
Primary Secondary adverse events The safety of such a therapeutic strategy will be assessed by systematic screening for adverse events at each conditioning session and at follow-up visits throughout the duration of exposure (8 weeks) by a trained experimenter, blinded to the therapeutic intervention.
All adverse events will be assessed and scored as a composite endpoint according to the NIH CCTAE 5.0 (National Institute of Health Common Terminology Criteria for Adverse Events), including in particular those listed in the sub-sections on "Cardiological Pathologies", "Central Nervous System Pathologies" and "Vascular Pathologies".
Through study completion, an average of 8 weeks
Secondary Fugl-Meyer Function - Fugl-Meyer motor function Score range: 0-100 Higher values indicate better performance. A score of 96-99 indicates light motor incoordination A score of 85-95 indicates hemiparesis A score = 84 indicates hemiplegia Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
Secondary New Functional ambulation category (nFAC) score Function - New Functional ambulation category (nFAC) score Score range: 0-5 A score of 0 indicates no functional ability to walk A score of 5 indicates independent walking Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
Secondary Prospective collection of number of falls Function - Prospective collection of number of falls Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
Secondary Modified Rankin Scale (mRS) Activity limitation - Modified Rankin Scale (mRS) Score range: 0-6 The mRS scores range from à (no symptom) to 6 (death) Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
Secondary Barthel index Activity limitation - Barthel index Score range: 0-100 The higher the score, the better the function and the independence Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
Secondary 16-item Stroke Impact Scale Participation The higher the score, the better the performance. Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
Secondary 10-metre walk test Mobility - Instrumented 10-metre walk test, carried out at spontaneous walking speed, 3 trials: collection of quantitative spatiotemporal step parameters and their variability, collection of walking speed. Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
Secondary Timed-up and Go test Mobility - Timed-up and Go test: 3 trials Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
Secondary Montreal Cognitive Assessment Neuropsychological assessment Score range: 0-30 Normal if >26/30 The higher the score, the better the cognitive performance. Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
Secondary Magnetic resonance imagery - Morphological sequences The acquisitions will be performed on a 3 Tesla magnetic resonance imaging (MRI) machine.
High-resolution anatomical sequences: T1, T2, FLAIR, for calculation of lesion volume and delineation of lesion mask.
Phase 1: Inclusion; Phase 2: Inclusion, 2 months, 6 months
Secondary Magnetic resonance imagery - Diffusion and perfusion sequences The acquisitions will be performed on a 3 Tesla magnetic resonance imaging (MRI) machine.
Bolus perfusion (gadolinium) T1 and Diffusion Tensor Imaging (DTI, 60 directions or High Angular Resolution Diffusion Imaging (HARDI)), allowing calculation of the Apparent Diffusion Coefficient (ADC) map.
Phase 1: Inclusion; Phase 2: Inclusion, 2 months, 6 months
Secondary Magnetic resonance imagery - Cerebral blood flow The acquisitions will be performed on a 3 Tesla magnetic resonance imaging (MRI) machine.
Cerebral vasoreactivity (to a hypercapnic stimulus) assessed by Arterial Spin Labelling (ASL) and Blood oxygenation level-dependent (BOLD) sequences.
Phase 1: Inclusion; Phase 2: Inclusion, 2 months, 6 months
Secondary Magnetic resonance imagery - Resting state functional magnetic resonance imaging (fMRI) The acquisitions will be performed on a 3 Tesla magnetic resonance imaging (MRI) machine.
Functional connectivity measurements.
Phase 1: Inclusion; Phase 2: Inclusion, 2 months, 6 months
Secondary Cerebral Blood Flow Cerebral blood flow will be assessed by measuring the flow velocity in the middle cerebral artery (MCAv), estimated by continuous measurement of the right middle cerebral artery using a 2 megahertz (MHz) pulsed transcranial Doppler (TCD) (MultiDop T, Compumedics Germany GmbH, Germany). Following standardized research techniques, the Doppler probe will be fixed to the temporal window with the aid of a helmet (DiaMon, Compumedics Germany GmbH) to maintain an optimal insonation position throughout the study and thus avoid any movement artifact. Phase 1: Inclusion; Phase 2: Inclusion, 2 months, 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT03993236 - Study on Rosuvastatin+Ezetimibe and Rosuvastatin for LDL-C Goal in Patients With Recent Ischemic Stroke Phase 4
Completed NCT04069767 - Innovative Physiotherapy in Stroke Rehabilitation N/A
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Enrolling by invitation NCT04956211 - Periodontal Treatment and Ischemic Stroke N/A
Active, not recruiting NCT05098236 - Effect of Visual Retraining on Visual Loss Following Visual Cortical Damage N/A
Completed NCT03942588 - High-intensity Interval Training After Stroke N/A
Recruiting NCT04949334 - Effects of Respiratory Muscle Training in Patients With Acute Ischemic Stroke N/A
Terminated NCT04095767 - Assessing Safety and Performance of the ANA Catheter System, Combined With a Stent Retriever in Acute Ischemic Stroke N/A
Withdrawn NCT04991038 - Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients N/A
Completed NCT01937182 - The Efficacy of Citalopram Treatment in Acute Stroke Phase 2
Completed NCT03649295 - Combined Conventional Speech Therapy and Functional Electrical Stimulation in Dysphagia Following Stroke N/A
Recruiting NCT05303649 - Effects of Neuronavigated Theta Burst Stimulation in Therapy of Post-stroke Aphasia N/A
Completed NCT04233515 - Use of Oral Anticoagulants and Symptoms in Patients With Atrial Fibrillation in Örebro County
Completed NCT05102877 - Sensory Versus Motor Level Neuromuscular Electrical Stimulation N/A
Completed NCT04089917 - A Study of the Use of the Q Aspiration Catheter to Remove Clot in Stroke Patients
Completed NCT05221112 - Effects of PNF Patterns Training on Trunk Balance, and Gait in Chronic Stroke Patients N/A
Not yet recruiting NCT05035953 - Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke Phase 2
Completed NCT06326801 - Resistive Diaphragmatic Breathing Exercise With Pursed Lips Breathing Exercise in Sub-acute Stroke Patients N/A
Recruiting NCT03826030 - Transcranial Direct Current Stimulation for Post-stroke Motor Recovery Phase 2
Recruiting NCT03839810 - Stochastic Resonance Stimulation in Brain Plasticity and Post Stroke Motor Recovery N/A